MX385451B - Proteínas sintéticas autoensamblables. - Google Patents

Proteínas sintéticas autoensamblables.

Info

Publication number
MX385451B
MX385451B MX2015012461A MX2015012461A MX385451B MX 385451 B MX385451 B MX 385451B MX 2015012461 A MX2015012461 A MX 2015012461A MX 2015012461 A MX2015012461 A MX 2015012461A MX 385451 B MX385451 B MX 385451B
Authority
MX
Mexico
Prior art keywords
self
present disclosure
immunogenic
limited
antigens
Prior art date
Application number
MX2015012461A
Other languages
English (en)
Spanish (es)
Other versions
MX2015012461A (es
Inventor
Daniel T Verhamme
Erik D´HONDT
Keith Alan Charlton
Original Assignee
Bioven 3 Ltd
Daniel T Verhamme
Erik D´Hondt
Keith Alan Charlton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioven 3 Ltd, Daniel T Verhamme, Erik D´Hondt, Keith Alan Charlton filed Critical Bioven 3 Ltd
Publication of MX2015012461A publication Critical patent/MX2015012461A/es
Publication of MX385451B publication Critical patent/MX385451B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2015012461A 2013-03-15 2014-03-17 Proteínas sintéticas autoensamblables. MX385451B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791268P 2013-03-15 2013-03-15
PCT/IB2014/001125 WO2014140894A2 (en) 2013-03-15 2014-03-17 Self-assembling synthetic proteins

Publications (2)

Publication Number Publication Date
MX2015012461A MX2015012461A (es) 2016-08-08
MX385451B true MX385451B (es) 2025-03-18

Family

ID=51225849

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015012461A MX385451B (es) 2013-03-15 2014-03-17 Proteínas sintéticas autoensamblables.
MX2021010021A MX2021010021A (es) 2013-03-15 2015-09-11 Proteínas sintéticas autoensamblables.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021010021A MX2021010021A (es) 2013-03-15 2015-09-11 Proteínas sintéticas autoensamblables.

Country Status (14)

Country Link
US (3) US10736948B2 (enExample)
EP (1) EP2970409A2 (enExample)
JP (1) JP6873530B2 (enExample)
KR (2) KR102391734B1 (enExample)
CN (2) CN105209481B (enExample)
AU (1) AU2014229561B2 (enExample)
BR (1) BR112015023402A2 (enExample)
CA (1) CA2904506A1 (enExample)
HK (1) HK1214606A1 (enExample)
IL (3) IL286537B (enExample)
MX (2) MX385451B (enExample)
MY (1) MY187936A (enExample)
RU (1) RU2747857C2 (enExample)
WO (1) WO2014140894A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12595297B2 (en) 2015-05-12 2026-04-07 In3Bio Ltd. Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors
CA3070034A1 (en) * 2017-07-18 2019-01-24 In3Bio Ltd. Synthetic proteins and therapeutic uses thereof
EP3986447A4 (en) * 2019-06-18 2023-08-16 Citranvi Biosciences, LLC RATIONALLY MANIPULATED CARRIER PROTEINS FOR VACCINES
CN120904351A (zh) * 2019-06-25 2025-11-07 因斯瑞拜奥有限公司 稳定的嵌合合成蛋白及其治疗用途
KR20220099990A (ko) 2019-11-07 2022-07-14 인3바이오 리미티드 비티로신 표적화 키나아제 억제제와 병용하여 성장 인자 항체를 사용하기 위한 방법 및 조성물
CN114019166B (zh) * 2021-09-27 2024-02-27 浙江省食品药品检验研究院 一种检测龙葵素的试纸条及其应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US6153203A (en) 1993-10-08 2000-11-28 Duotol Ab Immunological tolerance-inducing agent
EP0657175B1 (en) * 1993-12-09 2005-03-02 Centro de Inmunologia Molecular Vaccine comprising human autologous epidermal growth factor and use thereof
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CA2745736C (en) 1996-10-23 2016-11-22 The Trustees Of The University Of Pennsylvania Immunotherapy and improved vaccines
AU734180B2 (en) 1997-08-29 2001-06-07 Antigenics Llc Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
US20080249019A1 (en) * 1998-08-25 2008-10-09 Syntaxin, Ltd. Treatment of mucus hypersecretion
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001027144A2 (en) 1999-10-08 2001-04-19 Active Biotech Ab Ab5 toxin b subunit mutants with altered chemical conjugation characteristics
PE20020572A1 (es) * 2000-12-06 2002-07-31 Centro Inmunologia Molecular Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
DE60232603D1 (de) 2001-06-21 2009-07-23 Teijin Ltd Nahinfrarot-schutzfolie
GB0115382D0 (en) 2001-06-22 2001-08-15 Univ Bristol Mutant
EP1490481A4 (en) 2001-12-14 2005-12-07 Centocor Inc CLONAL CELL LINES OF MYELOMES FOR PRODUCING PROTEINS IN A CHEMICALLY DEFINED ENVIRONMENT
US8206965B2 (en) * 2002-03-15 2012-06-26 Cellectis S.A. Hybrid and single chain meganucleases and use thereof
DE602004031341D1 (de) * 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
JP4623625B2 (ja) 2003-07-24 2011-02-02 株式会社AMBiS ヘテロ型５量体組換えワクチン
US7320795B2 (en) * 2003-07-30 2008-01-22 Vaccine Research Institute Of San Diego Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof
KR20070004560A (ko) * 2003-12-05 2007-01-09 노오쓰웨스턴 유니버시티 성장 인자 전달을 위한 자가조립 펩티드 친양매성 화합물들및 관련 방법들
ATE555127T1 (de) 2004-02-11 2012-05-15 Angeletti P Ist Richerche Bio Fusionsproteine des karzinomembryonalen antigens und deren verwendungen
EP1921149A1 (en) * 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
US7946815B2 (en) 2007-03-27 2011-05-24 Siemens Energy, Inc. Airfoil for a gas turbine engine
CN101970498A (zh) 2007-10-25 2011-02-09 维文蒂阿生物技术公司 针对变体HnRNPG的癌相关表位的抗体及其应用
CN101945666A (zh) 2007-12-19 2011-01-12 Mivac发展股份公司 治疗自身免疫和过敏性疾病的组合物及方法
EP2288380B1 (en) 2008-06-09 2020-06-03 Bharat Biotech International Limited Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same
JP2010050586A (ja) 2008-08-20 2010-03-04 Nec Corp 通信装置及びそれに用いる装置コンポーネント複合冗長化方法
US20120088819A1 (en) * 2008-10-31 2012-04-12 Makoto Inoue Method for enhancing expression of recombinant protein
JP5734201B2 (ja) * 2008-12-19 2015-06-17 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディ及びその使用
JP2011097930A (ja) * 2009-10-07 2011-05-19 Hokkaido Univ 光活性化生理機能センサータンパク質
RU2480524C2 (ru) * 2010-09-13 2013-04-27 Учреждение Российской академии наук Институт биоорганической химии им. академии М.М. Шемякина и Ю.А. Овчинникова РАН Конструкция на основе белковой пары барназа-барстар и способ ее получения
AU2012222833B2 (en) * 2011-03-03 2017-03-16 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
CN102604993B (zh) 2012-01-10 2013-03-20 天津耀宇生物技术有限公司 免疫佐剂与幽门螺杆菌抗原融合蛋白口服疫苗及其制备方法

Also Published As

Publication number Publication date
WO2014140894A2 (en) 2014-09-18
CN111978409B (zh) 2024-01-26
RU2015143217A (ru) 2017-04-27
AU2014229561A1 (en) 2015-10-29
IL273051A (en) 2020-04-30
KR20150139513A (ko) 2015-12-11
HK1214606A1 (zh) 2016-07-29
US12433939B2 (en) 2025-10-07
IL273051B (en) 2021-10-31
JP6873530B2 (ja) 2021-05-19
US11419923B2 (en) 2022-08-23
IL286537A (en) 2021-10-31
BR112015023402A2 (pt) 2017-08-22
CN105209481A (zh) 2015-12-30
IL286537B (en) 2022-07-01
US20200297827A1 (en) 2020-09-24
CN111978409A (zh) 2020-11-24
IL241116B (en) 2020-03-31
KR102391734B1 (ko) 2022-04-29
AU2014229561B2 (en) 2018-06-07
RU2019109120A (ru) 2019-06-13
MX2021010021A (es) 2021-12-10
MY187936A (en) 2021-10-29
IL241116A0 (en) 2015-11-30
JP2016517402A (ja) 2016-06-16
KR102427429B1 (ko) 2022-08-01
US10736948B2 (en) 2020-08-11
US20160095910A1 (en) 2016-04-07
MX2015012461A (es) 2016-08-08
WO2014140894A3 (en) 2015-02-19
CA2904506A1 (en) 2014-09-18
US20230042534A1 (en) 2023-02-09
KR20210005294A (ko) 2021-01-13
CN105209481B (zh) 2020-08-25
RU2747857C2 (ru) 2021-05-17
EP2970409A2 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
CY1121934T1 (el) Αντισωματα anti-fcrn
MX2021010021A (es) Proteínas sintéticas autoensamblables.
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
CR20150258A (es) Anticuerpos anti-ceacam5 y usos de éstos
PH12017502390A1 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
CY1120740T1 (el) Βελτιωμενα ευλογοϊικα εμβολια
EA201891420A1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
EA201500208A1 (ru) Слитые белки, содержащие интерлейкин-10, и их применения
IL261354A (en) Human cancer cells comprising recombinant polynucleotides encoding human leukocyte antigen (hla) genes compositions comprising same and uses thereof
EA201791253A1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
MX2018005047A (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano.
CR20200409A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer (divisional 2018-0027).
MX2017014056A (es) Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos.
EA202091166A1 (ru) ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
PH12018500159A1 (en) Constructs targeting psa peptide/mhc complexes and uses thereof
TR201905619T4 (tr) Alerji aşısı olarak peptit taşıyıcı füzyon proteinleri.
EA201790239A1 (ru) Молекула-носитель для антигенов
PH12015500480A1 (en) Antibody formulations and uses thereof
EA201491784A1 (ru) Антитела против лигандов рецептора в1 брадикинина
EA201590187A1 (ru) Моноклональные антитела для применения в диагностике и терапии злокачественных опухолей и аутоиммунного заболевания
MX387764B (es) Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos.
EA201591796A1 (ru) Антитела к cd52
CL2012003458A1 (es) Vector que comprende un polipeptido antigénico de campylobacter; composicion farmacéutica que comprende dicho vector; uso del vector para mejorar respuesta inmune del sujeto al polipéptido antigénico.
BR112015023738B8 (pt) Vacinas de nucleoproteina influenza
MX2016004754A (es) Nuevo peptido que tiene cuatro epitopos de linfocitos t citotoxicos (ctl) enlazados.